A detailed history of Black Rock Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,258,808 shares of ARVN stock, worth $117 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,258,808
Previous 5,494,254 13.92%
Holding current value
$117 Million
Previous $227 Million 26.54%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $18.7 Million - $30.9 Million
764,554 Added 13.92%
6,258,808 $167 Million
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $5.07 Million - $7.29 Million
139,390 Added 2.6%
5,494,254 $227 Million
Q4 2023

Feb 13, 2024

BUY
$14.19 - $42.33 $5.47 Million - $16.3 Million
385,256 Added 7.75%
5,354,864 $220 Million
Q3 2023

Nov 13, 2023

BUY
$19.64 - $28.21 $1.3 Million - $1.87 Million
66,139 Added 1.35%
4,969,608 $97.6 Million
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $9.3 Million - $13.4 Million
427,871 Added 9.56%
4,903,469 $122 Million
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $3.12 Million - $4.45 Million
119,428 Added 2.74%
4,475,598 $122 Million
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $21.1 Million - $37.2 Million
649,662 Added 17.53%
4,356,170 $149 Million
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $1.31 Million - $1.82 Million
31,339 Added 0.85%
3,706,508 $165 Million
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $5.4 Million - $11.1 Million
149,910 Added 4.25%
3,675,169 $155 Million
Q1 2022

May 12, 2022

BUY
$60.27 - $81.57 $1.18 Million - $1.59 Million
19,519 Added 0.56%
3,525,259 $237 Million
Q4 2021

Feb 10, 2022

BUY
$65.85 - $96.21 $15.2 Million - $22.2 Million
230,284 Added 7.03%
3,505,740 $288 Million
Q3 2021

Nov 09, 2021

BUY
$73.2 - $107.87 $12.1 Million - $17.8 Million
165,086 Added 5.31%
3,275,456 $269 Million
Q2 2021

Aug 11, 2021

BUY
$60.45 - $84.26 $188 Million - $262 Million
3,110,370 New
3,110,370 $239 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.